# Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

> **NCT04074967** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dan Zandberg** · enrollment: 70 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Melanoma
- Solid Tumor
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Phase Ib ARRY-614 + nivolumab
- **DRUG:** Phase Ib ARRY-614 + nivolumab+ipilimumab
- **DRUG:** Phase II ARRY-614 + nivolumab
- **DRUG:** Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
- **DRUG:** Phase II ARRY-614 + nivolumab+ipilimumab (RCC)

## Key facts

- **NCT ID:** NCT04074967
- **Lead sponsor:** Dan Zandberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-11
- **Primary completion:** 2024-12-27
- **Final completion:** 2025-12-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074967, "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04074967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*